MM402 for Autism Spectrum Disorder
Phase 2
20
about 1.7 years
18–65
1 site in NY
What this study is about
Researchers are testing a treatment called MM402, which is an R-enantiomer of MDMA (R-MDMA), in adults with autism spectrum disorder. The trial will last 636 days and involve approximately 20 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
oral
Primary: Change from Baseline in 11-point Numerical Rating Scale (NRS) scores
Secondary: Pharmacokinetic Parameters (AUC0-24h), Pharmacokinetic Parameters (AUC0-inf), Pharmacokinetic Parameters (Cmax), Pharmacokinetic Parameters (Tmax), Pharmacokinetic Parameters (t1/2), Pharmacokinetic Plasma concentrations
Psychiatry / Mental Health